229 related articles for article (PubMed ID: 25711191)
1. Commercialized biomarkers: new horizons in prostate cancer diagnostics.
Murphy L; Prencipe M; Gallagher WM; Watson RW
Expert Rev Mol Diagn; 2015 Apr; 15(4):491-503. PubMed ID: 25711191
[TBL] [Abstract][Full Text] [Related]
2. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive biomarkers in prostate cancer.
Kontos CK; Adamopoulos PG; Scorilas A
Expert Rev Mol Diagn; 2015; 15(12):1567-76. PubMed ID: 26548550
[TBL] [Abstract][Full Text] [Related]
4. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
6. [Update on the diagnosis of PCa in urine. The current role of urine markers].
Fernandez-Serra A; Casanova-Salas I; Rubio L; Calatrava A; García-Flores M; García-Casado Z; López-Guerrero JA; Rubio-Briones J
Arch Esp Urol; 2015 Apr; 68(3):240-9. PubMed ID: 25948797
[TBL] [Abstract][Full Text] [Related]
7. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer.
Böttcher R; Hoogland AM; Dits N; Verhoef EI; Kweldam C; Waranecki P; Bangma CH; van Leenders GJ; Jenster G
Oncotarget; 2015 Feb; 6(6):4036-50. PubMed ID: 25686826
[TBL] [Abstract][Full Text] [Related]
8. Detection and Prognosis of Prostate Cancer Using Blood-Based Biomarkers.
Jin W; Fei X; Wang X; Song Y; Chen F
Mediators Inflamm; 2020; 2020():8730608. PubMed ID: 32454797
[TBL] [Abstract][Full Text] [Related]
9. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for prostate cancer detection.
Reed AB; Parekh DJ
Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890
[TBL] [Abstract][Full Text] [Related]
11. [New biomarkers to optimize the selection and follow up of patients with prostate cancer on active surveillance].
López-Guerrero JA; Casanova-Salas I; Fernández-Serra A; Rubio L; Calatrava A; García-Flores M; García-Casado Z; Rubio-Briones J
Arch Esp Urol; 2014 Jun; 67(5):462-72. PubMed ID: 24914846
[TBL] [Abstract][Full Text] [Related]
12. Exosomal microRNAs as liquid biopsy biomarkers in prostate cancer.
Wang J; Ni J; Beretov J; Thompson J; Graham P; Li Y
Crit Rev Oncol Hematol; 2020 Jan; 145():102860. PubMed ID: 31874447
[TBL] [Abstract][Full Text] [Related]
13. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
[TBL] [Abstract][Full Text] [Related]
14. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer.
Costa-Pinheiro P; Patel HR; Henrique R; Jerónimo C
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1349-58. PubMed ID: 25148431
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of prostate cancer by analyzing oxidative stress in human seminal plasma: developing unsophisticated tools for noninvasive prostate cancer diagnosis.
Barrio-Muñoz M; Abad-Gairín C; Amengual-Guedán JM; Prats-López J
Eur J Cancer Prev; 2016 Nov; 25(6):518-23. PubMed ID: 26633164
[TBL] [Abstract][Full Text] [Related]
17. [New biomarkers in prostate cancer].
Provenzano M
Praxis (Bern 1994); 2012 Jan; 101(2):115-21. PubMed ID: 22252593
[TBL] [Abstract][Full Text] [Related]
18. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
19. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]